What we do
At Vara, we believe better breast cancer detection should be a standard offering for every woman, everywhere. Our AI-powered software platform, developed in close collaboration with radiologists in Germany, leads to higher cancer detection, lower false positive rate and alleviates the repetitive workload involved in routine screening – proven in the largest prospective study in healthcare to date with ~500,000 participating women.
Our mission is to make breast cancer screening more effective, measurable, and accessible. By enhancing early detection and ensuring outcomes backed by clinical evidence, we’re proud to contribute to national efforts focused on improving women’s health.
Founded in 2018 as the first company to emerge from Europe’s leading AI venture studio, Merantix, Vara has grown into an international team of 25 driven professionals. Our diverse team brings together entrepreneurs, healthcare experts, and technology innovators united by a common goal: transforming breast cancer screening for the better.
Further information can be found on our website: www.vara.aiThe Mission
The winners of European AI for cancer screening are being decided right now. Countries are issuing their national AI recommendations and running large-scale government-funded trials.
Vara is uniquely positioned to lead this. We run ~50% of Germany's national breast cancer screening program and have published the largest prospective trial in the field (PRAIM, Nature Medicine, 463,000 women). We have regulatory certifications that took years to earn, a monitoring platform no one else has built, a dominant market position in Germany and distribution partners across 15+ countries.
Now, Vara is entering a new phase – and we're looking for someone to build it with us.